GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Debt-to-Equity

Repligen (Repligen) Debt-to-Equity : 0.36 (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Debt-to-Equity?

Repligen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $75.1 Mil. Repligen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $636.7 Mil. Repligen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,971.2 Mil. Repligen's debt to equity for the quarter that ended in Dec. 2023 was 0.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Repligen's Debt-to-Equity or its related term are showing as below:

RGEN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17   Med: 0.22   Max: 0.57
Current: 0.36

During the past 13 years, the highest Debt-to-Equity Ratio of Repligen was 0.57. The lowest was 0.17. And the median was 0.22.

RGEN's Debt-to-Equity is ranked worse than
63.48% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs RGEN: 0.36

Repligen Debt-to-Equity Historical Data

The historical data trend for Repligen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Debt-to-Equity Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.18 0.21 0.22 0.36

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.22 0.22 0.21 0.36

Competitive Comparison of Repligen's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Repligen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Repligen's Debt-to-Equity falls into.



Repligen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Repligen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Repligen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Repligen  (NAS:RGEN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Repligen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Repligen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines

From GuruFocus

Repligen to Report Second Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-19-2022

Repligen to Report First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-18-2023

Repligen Appoints Martin D. Madaus to Board of Directors

By sperokesalga sperokesalga 02-09-2023

Repligen Corporation to Present at Upcoming Investor Conferences

By sperokesalga sperokesalga 05-31-2023

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

By GuruFocusNews GuruFocusNews 06-25-2022

Repligen To Host Investor Day 2022

By PurpleRose PurpleRose 08-24-2022